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Hepatitis C virus (HCV) infection is a global health concern with chronic liver damage threatening 3% of
the world’s population. To date, the standard of care is a combination of pegylated interferon-alpha with
ribavirin, and recently two direct acting antivirals have entered the clinics. However, because of side
effects, drug resistance and viral genotype-speciﬁc differences in efﬁcacy current and potentially also
future therapies have their limitations. Here, we describe the development of a phenotypic high-through-
put assay to identify new cross-genotype inhibitors with novel mechanism of action, by combining a
genotype (gt) 1 replicon with the infectious HCV gt2 cell culture system. To develop this phenotypic
multiplex assay, HCV reporter cells expressing RFP-NLS-IPS and gt1b replicon cells expressing
NS5A-GFP were co-plated and treated with compounds followed by inoculation with gt2a HCV. At
72 h post treatment, RFP translocation as a marker for HCV infection and GFP ﬂuorescence intensity as
a marker for gt1 RNA replication were measured. Additionally, the total cell number, which serves as
an indicator of cytotoxicity, was determined. This phenotypic strategy supports multi-parameter data
acquisition from a single well to access cross-genotypic activity, provides an indication of the stage of
the viral life cycle targeted, and also assesses compound cytotoxicity. Taken together, this multiplex
phenotypic platform facilitates the identiﬁcation of novel compounds for drug development and
chemical probes for continuing efforts to understand the HCV life cycle.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Hepatitis C virus (HCV) is a major cause of chronic liver disease
affecting 3% of the world’s population (WHO, 2012). HCV replica-
tion is prone to high error rates leading to a large diversity of geno-
types and subtypes (Simmonds et al., 2005) with differences in
susceptibility to current treatment and outcome of disease. The
standard of care (SOC), a combination of pegylated interferon-
alpha (PEG-IFNa) and ribavirin (RBV), results in unsatisfactory
rates of sustained virologic response (SVR) of 40–50% for patients
infected with HCV genotype (gt) 1 and about 80% for those infected
with gt 2 or 3. Furthermore, this treatment regimen is associated
with severe side effects often responsible for low adherence to
treatment (Chevaliez and Pawlotsky, 2007; Hayashi and Takehara,
2006; Manns et al., 2006; Shepherd et al., 2007). Recently, the
addition of expensive direct-acting antiviral agents (DAAs) to theprevious SOC has improved the SVR rates in HCV gt1 infected
patients, but unfortunately accompanied by additional side effects
(Ghany et al., 2011). This emerging clinical data prompted us to
develop a high-throughput screen (HTS) assay to identify novel
antiviral targets.
Various strategies have been applied to screen compound
libraries to identify new HCV antivirals; e.g. target-based
enzymatic assays using the viral protease, helicase or polymerase.
Potentially promising compounds require secondary proﬁling in
more complex cell-based assays to assess membrane permeability,
protein interactions, and toxicity, all of which will be used to
improve the physiochemical, pharmacokinetic, and pharmacody-
namic properties during compound optimization. The develop-
ment of the HCV subgenomic replicon system (Lohmann et al.,
1999) enabled screening of small molecule libraries targeting both
viral and cellular targets in a more physiological context (Lemm
et al., 2010; Mondal et al., 2009). In 2005, an HCV gt2 infectious
clone was described supporting the production of infectious HCV
particles in cell culture (HCVcc), enabling for the ﬁrst time the
investigation of the full viral life cycle (Lindenbach et al., 2005;
Wakita et al., 2005; Zhong et al., 2005). An infectious cell culture
H.-Y. Kim et al. / Antiviral Research 99 (2013) 6–11 7system for full length HCV gt1 was reported which is the most
prevalent genotype worldwide (Li et al., 2012; Yi et al., 2006),
however, screening involving cell-culture adapted HCV have only
been performed for gt2 and gt1/2 chimeric viruses (Chockalingam
et al., 2010; Gastaminza et al., 2010; Gentzsch et al., 2011;
Wichroski et al., 2012).
In this context, by combining the gt1 replicon with the infec-
tious HCV gt2 cell culture system our goal was to develop a
high-throughput phenotypic assay to identify cross-genotype
antivirals with a novel mechanism of action. Our devised strategy
allows multiparameter data acquisition from a single well by a
phenotypic approach by combining (i) the identiﬁcation of novel
HCV inhibitors with cross-genotypic activity, (ii) indication of the
targeted stage of the virus life cycle, and (iii) early assessment of
compound induced cytotoxicity.A 
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Fig. 1. Constructs and concept of the phenotypic multiplex assay. (A) Protein structure o
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mitochondrial membrane (Jones et al., 2010). Schematic of the HCV gt2a reporter-free chi
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in green and red respectively is changed in response to the speciﬁcity of HCV inhibitorsTaking advantage of the observation that the mitochondrial
antiviral signaling protein (MAVS/IPS-1), located in the outer mito-
chondrial membrane, is a cellular substrate for the HCV NS3-4A
protease, Jones et al. developed a cell-based ﬂuorescent reporter
system allowing sensitive detection of HCV-infection in live cells
(Jones et al., 2010; Loo et al., 2006). Overexpression of a fusion pro-
tein consisting of the membrane anchored C-terminal IPS-1 do-
main linked to a nuclear localization signal (NLS) and red
ﬂuorescent protein (RFP) (Fig. 1A), enables monitoring HCV infec-
tion events by measuring the translocation of cytoplasmic local-
ized RFP into nucleus upon by NS3-4A protease mediated
cleavage between RFP-NLS and IPS-1 (Fig. 1A and B).
To establish the phenotypic multiplex assay, Huh-7.5 derived
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plated into one well (Fig. 1A). The experimental protocol can be
brieﬂy described as follows: 2,400 cells per well were plated into
384-well assay plates, at 24 h post-plating compounds were added
and after a 2 h incubation period at 37 C, cells were inoculated
with Jc1 (Lindenbach et al., 2006; Pietschmann et al., 2006), a re-
porter-free gt2a virus at a multiplicity of infection of 2 (Fig. 1A).
At 72 h post-infection, plates were ﬁxed with 2% paraformalde-
hyde, cell nuclei were stained with 10 lg/mL Hoechst-33342 and
images were taken with an automated confocal microscope (Imag-
eXpress Ultra, Molecular Device) at a magniﬁcation of 20.Nuclei identification
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Fig. 3. Assay evaluation with reference compounds by dose response curve (DRC) analysis. (A) Different concentrations of NM-107 were tested (10 points 3-fold serial
dilution from 292 lM) and analyzed according to the scheme shown in Fig. 2. Representative images and the respective concentrations are indicated. (B) Analyzed values
generated by image processing software for EC100 (100 lM) and for the DMSO control. (C) DRCs of various HCV inhibitors. From each concentration of compounds treatment,
gt1 RNA replication (green squares), gt2 HCVcc infection (red triangles), and cytotoxicity (black circles) were determined by percentage of GFP positive cells
(AvgPercentCellGFP), Ratio (RFP translocated nucleus) and cell counting (SumCellNumber), respectively. Each value were normalized using DMSO/EC100 control into
percentage of inhibition and shown in the graph with error bar of quadruplicate experiments. The table provides the EC50 and CC50 values calculated from sigmoidal ﬁtting
curves. (D) Early and late step inhibitors treatment. Representative images and the respective concentrations are indicated. Couple phenotype is highlighted by yellow circles.
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10 H.-Y. Kim et al. / Antiviral Research 99 (2013) 6–11localization in RFP-NLS-IPS reporter cells (Fig. 1C-u). Lack of RFP
translocation but maintenance of GFP signal would either mean a
gt2 speciﬁc inhibitor of replication (Fig. 1C-v) or a block at the vir-
al entry level (Fig. 1C-w), which can be tested in a secondary assay
by infection with a HCV gt 1a/2a chimera. If, later steps in the viral
life cycle are targeted preventing the release of infectious particles,
primarily infected RFP-NLS-IPS cells would initially be infected and
the translocation of RFP into the nucleus can be observed (Fig. 1C-
x). Production of progeny virus and spread will, however, be
inhibited resulting in a mixed pattern within the RFP-NLS-IPS cells
with two translocation positive cells in close proximity (‘couple
phenotype’) which is the result of primarily infection and cell divi-
sion during the 72 h assay period (Fig. 1B).
To analyze the data, in-house image analysis algorithms were
developed for the detection and quantiﬁcation of certain cellular
phenotypes (Fig. 2). Images from ﬁve ﬁelds per well were taken
in three different channels. The algorithm identiﬁes nuclei stained
with Hoechst (blue channel) and determines the total number of
cells, which along with nuclear size and intensity were used as
indicators of compound induced cytotoxicity (Fig 2B). In the green
channel, GFP ﬂuorescence intensity, which is proportional to HCV
gt1b RNA replication, is measured and expressed as percentage
of GFP positive cells. In the red channel, the software determines
the number of RFP-NLS-IPS expressing cells by RFP ﬂuorescence
intensity in either the nucleus or cytoplasm, and calculates the per-
centage of RFP translocation positive cells as a marker of HCVcc gt2
infection (Fig. 2).
The assay was validated by 10-points dose response curve
(DRC) analysis using NM-107 (20-C-methylcytidine) (Bassit et al.,
2008), a nucleoside NS5B inhibitor with cross-genotypic activity,
and A-837093 (Lu et al., 2007), a non-nucleoside NS5B inhibitor
speciﬁc for gt1 (Fig. 3). As expected, increasing concentrations of
NM-107, decreased both NS5A-GFP expression in the cytoplasm
(gt1b replicon) as well as RFP-NLS translocation into the nuclei
(gt2a HCVcc infection) (Fig. 3A). This can be quantiﬁed by image
processing as described in Fig. 2. A comparison of active concentra-
tions of NM-107 treatment (effective concentration giving 100%
inhibition; EC100) with DMSO solvent control is shown in Fig. 3B.
These data demonstrate that NM-107 efﬁciently inhibits both
gt1b replication (reduction of GFP expression) as well as gt2 infec-
tion (reduction of translocated RFP) without affecting cell growth
even at high concentrations (EC100) (nuclear parameters measured
in blue channel were unchanged). From these various outputs of
total cell number (SumCellNumber), percent of GFP expressing
cells (AvgPercentCellGFP), and RFP translocation cells (Ratio), DRCs
can be derived to assess cytotoxicity, gt1b RNA replication and gt2
HCVcc infection, respectively as illustrated in Fig. 3C for NM-107
and A-837093. Both gt1 RNA replication and gt2 HCVcc infection
were inhibited by NM-107 treatment in dose dependent manner
as shown in green and red, respectively. This antiviral effect was
not related to cytotoxicity that started to be detectable only at
the highest compound concentrations (grey area in Fig. 3C). The
EC50 of NM-107 was calculated from each DRC by non-linear
regression analysis using Prism (GraphPad Software, Inc.) at
4.06 lM against gt1 RNA replication and 6.1 lM against gt2 HCVcc
versus more than 300 lM for CC50 (cytotoxic concentration giving
50% cell death) (Fig. 3C). These values were comparable to pub-
lished data (Bassit et al., 2008) and non-multiplexed assays using
the gt1 replicon (4.46 ± 1.5 lM) or gt2 HCVcc (8.8 ± 2.2 lM). Like-
wise, a DRC analysis with A-837093 (Fig. 3C) resulted in dose
dependent antiviral activity against gt1 replicons but not against
gt2 HCVcc as shown by decreased GFP expression and unchanged
RFP localization respectively (Fig. 3C lower chart). We tested sev-
eral HCV inhibitors which have different mode of action to demon-
strate that this assay is suitable to identify inhibitors targeting
various steps in the viral life cycle (Fig. 3C table). Telaprevir, aNS3-4A protease inhibitor (Selleck Chemicals, USA) (Lin et al.,
2006), GS-7977, a NS5B inhibitor (Medchem Express, China)
(Murakami et al., 2010; Soﬁa et al., 2010), LY-411575, a late step
inhibitor (BOC Science, USA) (Wichroski et al., 2012), and an anti-
body serving as an entry inhibitor by targeting CD81 (BD Biosci-
ence, USA) were tested by 10-points DRC analysis as described
above. EC50 values of each inhibitor are comparable with previ-
ously reported data. In addition, we observed couple phenotype
which is the result of primarily infection and cell division during
the 72 h assay period in late step inhibitor treatment (Fig. 3D).
The multiplex system presented here facilitates the simulta-
neous evaluation of not only antiviral activity and cytotoxicity
but also provides basic mechanistic information. This strategy is
time and cost effective, as more information can be acquired in
comparison with classical assays using a single readout (e.g. lucif-
erase values). Importantly, our multiplex assay is compatible with
HTS. Furthermore, the spectrum of information gained in this one-
step-approach narrows down which step in the life cycle the com-
pound inhibits and facilitates a rapid inhibitor triage. Additionally,
by combining different HCV genotypes, enables to identify drug
candidates with cross-genotypic coverage and allowstriaging of
potentially genotype-speciﬁc compounds. Finally, the advantage
of monitoring cytotoxic effects in parallel reduces the probability
of selecting less favorable compounds. Taken together, the pheno-
typic assay described here facilitates the selection of antivirals
with a novel mechanisms of action, which are potential new ther-
apeutics and tools to elucidate the still poorly understood HCV life
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